Skip to main content

Table 2 Associations between COX expression levels and clinical covariates, the Vanderbilt TROC

From: Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors

  COX-1 / PTGS-1 COX-2 / PTGS-2
Standard IHC scoring H-Score Standard IHC scoring H-Score
Characteristic N (%) weak Moderate & strong P-value Mean (std err) P-value N (%) weak Moderate & strong P-value Mean (std err) P-value
Age
 < 57.6 39 (50.7) 56 (49.6) 0.883 91.2 (9.4) 0.889 46 (44.7) 49 (56.3) 0.109 77.6 (8.8) 0.047
 ≥ 57.6 38 (49.4) 57 (50.4) 93.0 (9.3) 57 (55.3) 38 (43.7) 54.6 (7.3)
Stage
 I/II 32 (41.6) 25 (22.1) 0.004 72.1 (11.9) 0.047 17 (16.5) 40 (46.0) < 0.001 111.5 (12.8) < 0.001
 III/IV/Unstaged 45 (58.4) 88 (77.9) 100.6 (7.9) 86 (83.5) 47 (54.0) 46.7 (5.4)
Histologic Subtype
 Serous 47 (61.0) 12 (10.6) < 0.001 116.5 (7.6) < 0.001 82 (79.6) 49 (56.3) < 0.001 49.7 (5.4) < 0.001
 Non-Serous 30 (39.0) 101 (89.4) 37.9 (9.7) 21 (20.4) 38 (43.7) 102.7 (13.2)
Grade
 Low Grade 15 (19.5) 18 (15.9) 0.526 92.4 (16.4) 0.982 5 (4.9) 28 (32.2) < 0.001 134.0 (16.1) < 0.001
 High Grade 62 (80.5) 95 (84.1) 92.0 (7.2) 98 (95.2) 59 (67.8) 51.9 (5.5)
Type
 Type I Tumors 39 (50.7) 26 (23.0) < 0.001 68.4 (11.1) 0.009 19 (18.5) 46 (52.9) < 0.001 113.4 (12.2) < 0.001
 Type II Tumors 38 (49.4) 87 (77.0) 104.4 (8.0) 84 (81.6) 41 (47.1) 41.5 (4.8)
Residual Diseasea
 Optimal 22 (43.1) 25 (29.4) 0.103 78.4 (12.2) 0.177 16 (21.1) 31 (51.7) < 0.001 109.1 (14.0) < 0.001
 Suboptimal 29 (56.9) 60 (70.6) 97.3 (9.3) 60 (79.0) 29 (48.3) 42.4 (6.1)
Platinum Sensitivityb
 Resistant 12 (30.0) 27 (33.8) 0.679 93.0 (13.6) 0.884 28 (40.0) 11 (22.0) 0.038 37.7 (8.7) 0.030
 Sensitive 28 (70.0) 53 (66.3) 95.5 (9.7) 42 (60.0) 39 (78.0) 63.8 (8.2)
  1. Bold values denote signficant associations; column percentages may not sum to 100% due to rounding error
  2. aAmong cases with known cytoreductive status
  3. bAmong cases treated with platinum with response to treatment known